The most robust clinical evidence arguably originates from the large cardiovascular outcomes trials (CVOTs) completed for most GLP-1 RAs, of which the latest showed a significant relative risk reduction (RRR) of 39% (HR) with once-weekly efpeglenatide on HF requiring hospitalisation, corroborating a meta-analysis which found a significant RRR across eight GLP-1 RA CVOTs of 11%
Keep the needle in place for at least 6 seconds to ensure the full dose is delivered
For meal ideas that combine all these elements, see our GLP-1 breakfast ideas and dinner recipes
Nooms care team can assist with prior authorizations and manufacturer coupons

Abbreviations AE Adverse event BMI Body mass index CFR Code of Federal Regulations CI Confidence interval CSF Cerebrospinal fluid EHR Electronic health record GI Gastrointestinal GIP Glucosedependent insulinotropic polypeptide GLP-1 Glucagonlike peptide-1 GLP-1 RA GLP-1 receptor agonist GRADE Grading of Recommendations, Assessment, Development and Evaluations ICD-10 International Classification of Diseases, 10th Revision ICP Intracranial pressure IIH Idiopathic intracranial hypertension IQR Interquartile range NKCC1 NaKCl cotransporter 1 OCT Optical coherence tomography ONSF Optic nerve sheath fenestration OR Odds ratio PMD Perimetric mean deviation PRISMA Preferred Reporting Items for Systematic Reviews and MetaAnalyses RA Receptor agonist RCT Randomized controlled trial RNFL Retinal nerve fiber layer ROBINS-I Risk Of Bias In Nonrandomized Studies of Interventions RR Risk ratio SAE Serious adverse event SD Standard deviation Authors contributions J.O.: Conceptualization, Formal analysis, Visualization, Data curation, Validation, Writing: Original Draft, Writing: Review & Editing

Retrieved from GLP-1 Agonists